Vascular News‘ live conference coverage, an interview with Kevin Mani (Uppsala University Hospital, Uppsala, Sweden), and several industry updates feature in October’s top 10.
1. Cook Medical creates custom-made aortic device for fenestrated FET procedure
According to Cook Medical, a frozen elephant trunk (FET) procedure had never before been performed with a custom-made device that had a fenestration. Adding a fenestration in the aortic graft removed the need for surgical intervention for the left subclavian artery (LSA) vessel, allowing for a smooth endovascular LSA stenting and a streamlined, more minimally invasive procedure, the company noted.
2. EVES Summit 2024: Integrate, elevate, and innovate
Ahmed Eleshra (Mansoura University, Mansoura, Egypt) and Sherif Elkerdawi (Wadi Elneel Hospital, Cairo, Egypt) write together about the Egyptian Vascular and Endovascular Society (EVES) 2024 Summit (30 October–1 November, Cairo, Egypt), touching on the state of vascular surgery in Egypt, the main goals of organising a unified congress, and three forums that promise to be highlights of the meeting’s programme.
3. Profile: Kevin Mani
“We need to continue to build the scientific evidence base for what we do,” Kevin Mani (Uppsala, Sweden) tells Vascular News, underlining what he believes to be a key priority for vascular surgery in the years ahead, in this interview. Research has been central to Mani’s career so far, forming a crucial part of his surgical residency and pathway into vascular surgery and culminating in his current role as professor and chief of vascular surgery at Uppsala University Hospital and chair of the Swedish Vascular Registry (Swedvasc). Mani also shares one of his most memorable cases to date, recalling the successful treatment of a young patient with complex aortic disease—an experience that for him exemplified the value of continued technological innovation and teamwork in vascular surgery.
4. EVES 2024 live blog
Last week Vascular News was reporting live from the inaugural Egyptian Vascular and Endovascular Society (EVES) 2024 Summit (30 October–1 November, Cairo, Egypt).
5. Surmodics receives US FDA 510(k) clearance for Pounce XL thrombectomy system
The Pounce XL thrombectomy system is indicated for the non-surgical removal of thrombi and emboli from the peripheral arterial vasculature in vessels 5.5–10mm in diameter, making it suitable for iliac, femoral, and other arteries within this range.
6. CX Aortic Live blog
CX Aortic Live 2024 (7–8 October, Vienna, Austria) featured live case transmissions, edited cases and podium presentations on the latest cardiac, vascular and endovascular aortic advances.
7. Carotid endarterectomy ‘remains useful and relevant’ in era of improving medical therapy
Findings from a retrospective analysis presented at the recent European Society for Vascular Surgery (ESVS) annual meeting (24–27 September, Kraków, Poland) provide evidence that—for symptomatic carotid artery stenosis patients—endarterectomy “remains a useful and relevant intervention in the era of improving medical therapy”.
8. Endospan completes enrolment of primary arm in TRIOMPHE IDE clinical study
The TRIOMPHE investigational device exemption (IDE) clinical study—a three-arm non-randomised study conducted at 30 aortic centres across the USA and one centre in New Zealand—is evaluating the safety and efficacy of the the Nexus aortic arch stent graft for the treatment of aortic arch disease.
9. Carotid intervention linked to improved survival versus medical management in symptomatic patients
New study data suggest that the interventional treatment of symptomatic carotid artery disease may result in an improved rate of age-adjusted overall survival compared to medical management. However, the same study—presented at this year’s European Society for Vascular Surgery (ESVS) annual meeting (24–27 September, Kraków, Poland)—also indicates a relatively low future ipsilateral stroke risk among patients who were not offered carotid intervention, highlighting medical management’s importance as a standalone strategy in patients deemed to be ‘high risk’ if treated via intervention.
10. Contego Medical’s Neuroguard IEP system receives US FDA approval for carotid revascularisation
The company shares in a press release that clinical studies of the Neuroguard IEP system, including the PERFORMANCE I trial and PERFORMANCE II investigational device exemption (IDE) trial, have consistently recorded “unprecedented” low event rates—zero major strokes, zero neurologic deaths, and zero stent thrombosis at 30 days and one year.
